Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07204964 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

A Phase 2 study of Influenza, Human, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 2
Development phase
960
Enrollment target
17
Study locations

NCT07204964 is a Phase 2 study of Influenza, Human that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 960 participants, below the 16,170-participant average among 18 other Influenza, Human trials with a reported enrollment target (94% lower). The trial reports 17 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07204964, a Phase 2 study of Influenza, Human, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 2
Development phase
960 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults.

Conditions Studied

Influenza, Human

Interventions

  • BIOLOGICAL Flu mRNA (Formulation B1)
  • BIOLOGICAL Flu mRNA (Formulation B3)
  • BIOLOGICAL Flu mRNA(Formulation A)
  • COMBINATION_PRODUCT Comparator 1
  • COMBINATION_PRODUCT Comparator 2

Study Locations (17)

Florida

  • GSK Investigational Site - Hialeah
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Pembroke Pines

California

  • GSK Investigational Site - Canoga Park
  • GSK Investigational Site - Walnut Creek

Nevada

  • GSK Investigational Site - Carson City
  • GSK Investigational Site - Las Vegas

Texas

  • GSK Investigational Site - Austin
  • GSK Investigational Site - Garland

Other

  • GSK Investigational Site - Edegem
  • GSK Investigational Site - Ghent

Alabama

  • GSK Investigational Site - Guntersville

Georgia

  • GSK Investigational Site - Stockbridge

North Carolina

  • GSK Investigational Site - Greensboro

Trial Details

FieldValue
Enrollment Target 960 participants
Start Date 2025-10-07
Est. Completion 2026-09-17
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07204964

The ClinicalTrials.gov registry entry for NCT07204964 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 960 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 16,170-participant average among 18 other Influenza, Human trials with a reported enrollment target (94% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Influenza, Human appearing as the primary indexed condition, and to 5 interventions - of which Flu mRNA (Formulation B1) is the first listed.

NCT07204964 reports 17 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Nevada.

Frequently Asked Questions

What is clinical trial NCT07204964 about?

NCT07204964 is a clinical study titled "A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above". The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults.

What is the current status of trial NCT07204964?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 960 participants. The study started on 2025-10-07. Estimated completion is 2026-09-17.

What conditions does trial NCT07204964 study?

This clinical trial studies the following conditions: Influenza, Human.

What interventions are being tested in trial NCT07204964?

The interventions under investigation include: Flu mRNA (Formulation B1) (BIOLOGICAL), Flu mRNA (Formulation B3) (BIOLOGICAL), Flu mRNA(Formulation A) (BIOLOGICAL), Comparator 1 (COMBINATION_PRODUCT), Comparator 2 (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT07204964?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07204964 being conducted?

This trial has 17 study locations across Alabama, California, Florida, Georgia, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Influenza, Human

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Influenza, Human

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.